Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.

@article{Valenti2012ImplicationsOP,
  title={Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.},
  author={Luca Valenti and A Aghemo and Albert Friedrich Staettermayer and Paolo Maggioni and Stella De nicola and Benedetta Maria Motta and M G Rumi and Paola Dongiovanni and P Ferenci and Massimo Colombo and Silvia Fargion},
  journal={Alimentary pharmacology & therapeutics},
  year={2012},
  volume={35 12},
  pages={1434-42}
}
BACKGROUND Homozygosity for the PNPLA3 p.I148M polymorphism influences steatosis and fibrogenesis in chronic hepatitis C (CHC). AIM To evaluate the effect of p.148M/M on sustained virological response (SVR) and viral kinetics in patients who underwent antiviral therapy with peg-interferon and ribavirin, stratified according to viral genotype and fibrosis severity, and secondarily, the interaction with interleukin-28B ( IL28B ) genotype on liver damage. METHODS In this observational study… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

An IL 28 B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis c genotype 4

  • S DeNicola, A Aghemo, MG Rumi
  • Hepatology
  • 2011

An IL28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis c genotype

  • S De Nicola, A Aghemo, MG Rumi
  • Hepatology
  • 2011
1 Excerpt

Bene fi cial IL 28 B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C

  • HL Tillmann, K Patel, AJ Muir
  • J Hepatol
  • 2011

Similar Papers

Loading similar papers…